Thus, we hypothesized that causing DNA damage (via 5-FU) and impairing DNA damage response (via PARP inhibition) could be a potential strategy to recreate 5-FU sensitivity in colorectal tumors with MMR deficient background. Here, MRC1 is linked to colorectal neoplasm.